Please provide your email address to receive an email when new articles are posted on . The progression of diabetic macular edema to clinically significant macular edema requiring photocoagulation may ...

Please provide your email address to receive an email when new articles are posted on . The decision is supported by positive visual acuity gains found in the phase 3 QUASAR trial. This is the fourth ...

Macular edema is the leading cause of visual loss in uveitic patients, and is a predictable feature of pars planitis, Behcet's and sarcoid uveitis, HLA-B27 related uveitis, and birdshot ...

Credit: Shutterstock. Findings showed faricimab was associated with rapid drying of retinal fluid. The Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window SAN FRANCISCO -- ...

‒ Post-hoc analyses from four Phase III studies indicate Vabysmo dried retinal fluid faster with fewer injections in wet age-related macular degeneration (AMD) and diabetic macular edema (DME) – ‒ ...

If approved, EYLEA HD would be the first and only treatment for RVO indicated for up to every 8-week dosing after an initial monthly dosing period – halving the number of injections that are indicated ...

Investigators analyzed retinal hemorrhages and macular edema events in patients treated with roxadustat or darbepoetin alfa. The risk of developing ophthalmic abnormalities appears no higher with ...

Credit: Shutterstock. Tarcocimab tedromer is an investigational VEGF inhibitor designed to improve bioavailability and intraocular half-life using the Company’s antibody biopolymer conjugate platform.